






Ordering JELMYTO Quick Reference Guide

This handy reference guide will help streamline order set input time for JELMYTO by giving you commonly requested information for the most widely used EMR systems. Now you can have confidence knowing the billing and reimbursement information you have is correct.

Which service lines/formularies should JELMYTO be added to?	Urology and/or oncology
Which hospitals/ASC/clinics will dispense JELMYTO?	Your organization information here
 Drug description	JELMYTO (mitomycin) for pyelocalyceal solution is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO uses reverse-thermal hydrogel to fill and conform to the renal anatomy for sustained mitomycin exposure
Generic drug name	Mitomycin for pyelocalyceal solution
Brand name	JELMYTO
 Drug strength/vial size	Supplied as two 40 mg vials for a total of 80 mg per kit
Drug form	Lyophilized powder
Default NDC	72493-103-03 72493-0103-03
Wholesale Acquisition Cost	\$25,445 (340B available upon request)
Is this drug considered hazardous?	Yes
HCPCS billing code	J9281 (permanent J code). Bill waste to JW9281. See How to Bill Guide
Drug unit for HCPCS code	1 mg
 Default frequency	Once a week for 6 weeks
Default dose	Patient-specific dose cannot exceed 60 mg. Refer to Prescribing Information
 Returned Goods Policy	Covers many different scenarios if JELMYTO is not instilled as planned. Scan QR code or click here for details
Is this drug refrigerated?	No
 Order/label instructions	Instill via ureteral catheter or nephrostomy tube (for outpatient use only). Advise patients that JELMYTO may discolor urine to a violet to blue color. Patients should avoid contact with urine for at least six hours post-instillation, void urine sitting on a toilet, and flush the toilet several times after use
Administration instructions	For pyelocalyceal use only



Have questions or need support? [Contact UroGenSupport.com](https://UroGenSupport.com) or call 833-UROGEN1 (833-876-4361)

Please see Important Safety Information on next page.



INDICATIONS AND USAGE

JELMYTO® (mitomycin) for pyelocalyceal solution is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).

IMPORTANT SAFETY INFORMATION

Contraindications

JELMYTO® (mitomycin) for pyelocalyceal solution is contraindicated in patients with perforation of the bladder or upper urinary tract.

Warnings and Precautions

Ureteric Obstruction

Ureteric obstruction, including ureteral stenosis and hydronephrosis, occurred in patients receiving JELMYTO. Monitor patients for signs and symptoms of ureteric obstruction, including flank pain, and fever, and for changes in renal function. Patients who experience obstruction may require transient or long-term ureteral stents or alternative procedures. Withhold or permanently discontinue JELMYTO based on the severity of ureteric obstruction.

Bone Marrow Suppression

The use of JELMYTO can result in bone marrow suppression, particularly thrombocytopenia and neutropenia. The following tests should be obtained prior to each treatment: Platelet count, white blood cell count differential and hemoglobin. Withhold JELMYTO for Grade 2 thrombocytopenia or neutropenia. Permanently discontinue for Grade 3 or greater thrombocytopenia or neutropenia.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, JELMYTO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with JELMYTO and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with JELMYTO and for 3 months following the last dose.

Adverse Reactions

Common Adverse Reactions

The most common adverse reactions in $\geq 20\%$ of patients treated with JELMYTO were ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, nausea, abdominal pain, fatigue, dysuria, and vomiting.

Additional Adverse Reactions Information

Selected clinically relevant adverse reactions in $< 10\%$ and $\geq 2\%$ of patients who received JELMYTO include urinary tract inflammation, bladder spasm, urosepsis, hypersensitivity, and instillation site pain.

Use in Specific Populations

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with JELMYTO and for 1 week following the last dose.

Preparation and Administration Information

JELMYTO is for pyelocalyceal use only and not for intravenous use, topical use, or oral administration. JELMYTO must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the JELMYTO Instructions for Pharmacy and administration instructions found in the JELMYTO Instructions for Administration.

JELMYTO may discolor urine to a violet to blue color following the instillation procedure. Advise patients to avoid contact with urine for at least six hours post-instillation, to void urine sitting on a toilet, and to flush the toilet several times after use.

JELMYTO is a hazardous drug. Follow applicable special handling and disposal procedures.

Please [click here](#) for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.

